Author Correction: Deconvolution of clinical variance in CAR-T cell pharmacology and response.
作者信息
Kirouac Daniel C, Zmurchok Cole, Deyati Avisek, Sicherman Jordan, Bond Chris, Zandstra Peter W
机构信息
Notch Therapeutics, Vancouver, BC, Canada.
School of Biomedical Engineering and Michael Smith Laboratories, University of British Columbia, Vancouver, BC, Canada.
出版信息
Nat Biotechnol. 2023 Nov;41(11):1655. doi: 10.1038/s41587-023-01816-6.
Abstract
摘要
相似文献
1
Author Correction: Deconvolution of clinical variance in CAR-T cell pharmacology and response.作者更正：嵌合抗原受体T细胞药理学和反应中临床差异的反卷积
Nat Biotechnol. 2023 Nov;41(11):1655. doi: 10.1038/s41587-023-01816-6.
2
Best Practices and Considerations for Clinical Pharmacology and Pharmacometric Aspects for Optimal Development of CAR-T and TCR-T Cell Therapies: An Industry Perspective.细胞治疗药物临床药理学和药效学考量与最佳开发的行业视角：嵌合抗原受体 T 细胞（CAR-T）和 TCR-T 细胞疗法
Clin Pharmacol Ther. 2023 Sep;114(3):530-557. doi: 10.1002/cpt.2986. Epub 2023 Jul 26.
3
Deconvolution-based partial volume correction in Raclopride-PET and Monte Carlo comparison to MR-based method.基于去卷积的雷氯必利正电子发射断层扫描中的部分容积校正及与基于磁共振成像方法的蒙特卡罗比较
Neuroimage. 2008 Feb 15;39(4):1570-84. doi: 10.1016/j.neuroimage.2007.10.038. Epub 2007 Nov 7.
4
Early Survival Prediction Framework in CD19-Specific CAR-T Cell Immunotherapy Using a Quantitative Systems Pharmacology Model.使用定量系统药理学模型的CD19特异性CAR-T细胞免疫疗法早期生存预测框架
Cancers (Basel). 2021 Jun 3;13(11):2782. doi: 10.3390/cancers13112782.
5
Pharmacology of Chimeric Antigen Receptor-Modified T Cells.嵌合抗原受体修饰 T 细胞的药理学。
Annu Rev Pharmacol Toxicol. 2021 Jan 6;61:805-829. doi: 10.1146/annurev-pharmtox-031720-102211. Epub 2020 Oct 9.
6
Clinical Pharmacology and Determinants of Response to UCART19, an Allogeneic Anti-CD19 CAR-T Cell Product, in Adult B-cell Acute Lymphoblastic Leukemia.临床药理学和对同种异体抗 CD19 CAR-T 细胞产品 UCART19 的反应决定因素，在成人 B 细胞急性淋巴细胞白血病中的作用。
Cancer Res Commun. 2022 Nov 30;2(11):1520-1531. doi: 10.1158/2767-9764.CRC-22-0175. eCollection 2022 Nov.
7
Chimeric antigen receptor (CAR) T-cell therapy for people with relapsed or refractory diffuse large B-cell lymphoma.嵌合抗原受体 (CAR) T 细胞疗法治疗复发或难治性弥漫性大 B 细胞淋巴瘤患者。
Cochrane Database Syst Rev. 2021 Sep 13;9(9):CD013365. doi: 10.1002/14651858.CD013365.pub2.
8
Recent advances and clinical pharmacology aspects of Chimeric Antigen Receptor (CAR) T-cellular therapy development.嵌合抗原受体（CAR）T 细胞疗法开发的最新进展和临床药理学方面。
Clin Transl Sci. 2022 Sep;15(9):2057-2074. doi: 10.1111/cts.13349. Epub 2022 Jul 2.
9
Author Correction: Determinants of response and resistance to CD19 chimeric antigen receptor (CAR) T cell therapy of chronic lymphocytic leukemia.作者更正：慢性淋巴细胞白血病对CD19嵌合抗原受体（CAR）T细胞疗法反应和耐药的决定因素。
Nat Med. 2021 Mar;27(3):561. doi: 10.1038/s41591-021-01248-2.
10
Partial volume effect correction in PET using regularized iterative deconvolution with variance control based on local topology.基于局部拓扑结构的方差控制正则化迭代反卷积在PET中的部分容积效应校正
Phys Med Biol. 2008 May 21;53(10):2577-91. doi: 10.1088/0031-9155/53/10/009. Epub 2008 Apr 25.
引用本文的文献
1
A phase I/II trial of WT1-specific TCR gene therapy for patients with acute myeloid leukemia and active disease post-allogeneic hematopoietic cell transplantation: skewing towards NK-like phenotype impairs T cell function and persistence.一项针对急性髓系白血病患者和异基因造血细胞移植后活动性疾病患者的WT1特异性TCR基因治疗I/II期试验：向NK样表型倾斜会损害T细胞功能和持久性。
Nat Commun. 2025 Jun 5;16(1):5214. doi: 10.1038/s41467-025-60394-0.
2
Acute Myeloid Leukemia Skews Therapeutic WT1-specific CD8 TCR-T Cells Towards an NK-like Phenotype that Compromises Function and Persistence.急性髓系白血病使治疗性WT1特异性CD8 T细胞受体T细胞向自然杀伤细胞样表型转变，从而损害其功能和持久性。
medRxiv. 2024 Dec 16:2024.12.13.24318504. doi: 10.1101/2024.12.13.24318504.
Zotero 插件